echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The development focus of traditional Chinese medicine innovative pharmaceutical enterprises, long-term opportunities are emerging

    The development focus of traditional Chinese medicine innovative pharmaceutical enterprises, long-term opportunities are emerging

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Traditional Chinese medicine is one of the characteristics of Chinese medicine, in recent years, the approval speed of domestic innovative Chinese medicine drugs has increased significantly, and Chinese medicine innovative drugs and exclusive varieties have a greater competitive advantage in medical insurance procurement, in this context, some pharmaceutical companies have begun to take traditional Chinese medicine innovative drugs as the focus
    of the company's development.

     
    For example, Chengdu Kanghong Pharmaceutical said that the company has long adhered to independent innovation of core products and actively promoted the application of technology in the field of
    traditional Chinese medicine.
    According to reports, in order to promote technological innovation, the company has established a holding subsidiary, Sichuan Honghe Pharmaceutical, last year, focusing on the research and development of innovative drugs in synthetic biology, thereby breaking the "bottleneck"
    in the development of druggability of active molecules of traditional Chinese medicine.
    "At present, the company is actively promoting the implementation of a series of high-quality clinical studies, continuously improving the evidence-based evidence of proprietary Chinese medicines, promoting the integration of Chinese and Western medicine, and supporting the inheritance and innovative development of
    Chinese medicine.
    "
     
    Tasly Pharmaceutical Group is committed to promoting the modernization and internationalization of traditional Chinese medicine, and on the basis of inheriting and giving full play to the original advantages of traditional Chinese medicine such as people-oriented and compound matching, it has promoted the innovation and development of modern traditional Chinese medicine, and has been approved as the "State Key Laboratory of Key Technologies of Innovative Chinese Medicine" by the Ministry of Science and Technology, and has created a number of large varieties
    of traditional Chinese medicine with "clear efficacy and well received" such as compound danshen drop pills.

     
    The industry said that in recent years, with the blessing of policies, long-term opportunities for innovative drugs in traditional Chinese medicine are emerging
    .
    It is reported that at present, many traditional Chinese medicine enterprises such as Panlong Pharmaceutical and Guizhou Bailing have adopted the method of cooperation with large hospitals to carry out the cooperative development of new drugs for in-hospital preparations, and some enterprises such as Ling Pharmaceutical rely on the hospitals under the parent company to carry out the transformation
    of in-hospital preparations.

     
    Under the continuous layout of enterprises, breakthroughs
    have also been made in the field of innovative traditional Chinese medicine.
    The data shows that in 2021, more than ten innovative traditional Chinese medicine drugs, such as lung cleansing and detoxification granules, kidney nourishing and calming tablets, Yiqi Tongqiao pills, and Yinqiao clear heat tablets, were intensively approved for marketing, becoming more than one year
    approved in the past five years.
    In 2022, two pharmaceutical preparations, Icariin (Acoladine, Icaritin) softgels of Beijing Sinokey Pharmaceutical, and Guangqian total flavonoid capsules of Renfu Pharmaceutical, were approved for marketing
    .

     
    In addition, data shows that since 2022, a total of 6 innovative Chinese medicine drugs have submitted marketing applications, of which 2 are antidepressants
    .
    For example, on September 29, Jianmin Pharmaceutical's marketing application for Class 1.
    1 Chinese proprietary medicine Pediatric Zibei cough syrup was accepted by CDE, which is the sixth innovative Chinese medicine drug declared for marketing this year
    .
    In addition, Olantigastric tablets is a class 1.
    2 new drug of traditional Chinese medicine independently developed by Jiangxi Qingfeng Pharmaceutical, which is an oral solid preparation made of total flavonoid glycoside extract extracted from Jiangxi authentic medicinal herb Citrus aurantium, mainly containing active ingredients
    such as naringenin and neohesperidin.

     
    Zhenbao Island also said in a recent survey by institutions that in terms of innovative traditional Chinese medicine drugs, the two varieties that are currently making faster progress are Qingxian and Gastric Fang, and the other is Qiang Huosheng Wet Soup
    .
    At present, the research and development is progressing smoothly, because in March 2022, the state issued an approval document on innovative drugs in traditional Chinese medicine, and the process of innovative drugs in traditional Chinese medicine has greatly shortened the research and development cycle
    from the beginning of project approval to commercialization compared with the original R&D progress of phases 1, 2 and 3.

     
    Analysts pointed out that now pharmaceutical companies are seeking a shortcut for the development of new drugs, and this shortcut is the classic formula, as well as the nosocomial preparation, the state has now introduced the "three combination" policy, there are certain development opportunities
    .
    At present, some large pharmaceutical companies have reached strategic cooperation with some traditional Chinese medicine hospitals, and through cooperation with famous experts and hospitals, they have accumulated human experience, and developed some prescriptions and in-hospital preparations based on classic prescriptions
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.